Practical Sustainability Metrics for Pharma
July 29th 2025In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle, dives into the metrics pharma companies can track today in order to measure distribution-related sustainability performance.
Unlocking Sustainability Across the Supply Chain
July 28th 2025In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle, explains the meaning behind Scope 3 emissions, including why they pose such a challenge for pharma manufacturers.
Scaling Obesity Drugs Responsibly
July 28th 2025In the fourth part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, explains the market dynamics or stakeholder misalignments that need to be resolved in order for the next generation of weight-loss drugs to reach scale without overburdening payers.
Peer Exchange: Supply Chain Blind Spots Threatening Pharma Integrity (Episode 5)
July 25th 2025In the fifth part of this roundtable discussion, a panel of KOLs explore how the chain of custody and chain of ownership are impacted by supply chain challenges, such as last-mile distribution and DSCSA data security.
How Pharma Executives Can Prepare for Tariff Uncertainty
July 25th 2025In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, covers the operational or strategic steps that pharma executives ought to be taking now in order to mitigate risks while awaiting clarity on tariff implementation.
Leveraging Digital Twins and Analytics to Optimize Global Pharma Supply Chains
July 24th 2025In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, outlines the role digital supply chain tools and analytics can play in helping manufacturers respond to pricing and sourcing volatility caused by sudden policy shifts.
Innovative Paths to Obesity Medication Access
July 24th 2025In the third part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, outlines alternative reimbursement or value-based contracting models that could be feasible in the short term, given CMS’ decision not to finalize coverage for obesity meds in 2026.
Building Inventory and Navigating FDA Hurdles in a Tariff-Driven Market
July 23rd 2025In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, comments on how pharma companies should prioritize reshoring strategies in response to these tariff threats, especially when infrastructure isn’t yet in place.
The Ripple Effect of 200% Tariffs on US Drug Supply and Pricing
July 22nd 2025In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, describes the immediate and long-term impacts of this potential levy on pharma imports.
Balancing Awareness and Assurance
July 21st 2025In the final part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, offers communication strategies for staying confident in genuine pharmaceuticals while also remaining vigilant against counterfeit threats.
Creating a Unified Strategy to Advance Education on Counterfeit Medicines
July 16th 2025In the second part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, explains how the private sector should strategically support and scale efforts to ensure that HCPs globally receive substandard and falsified medicine detection training.
Balancing Innovation and Lifecycle Strategy in the Era of the IRA
July 16th 2025In the third part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, explains the strategies that manufacturers should adopt to balance investment in innovation with lifecycle management.
Why Medical Education Must Catch Up
July 15th 2025In the first part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, lays out the systemic gaps in medical and pharmacy education that need to be addressed, along with how academic and clinical institutions can accelerate awareness training in identifying substandard and falsified medicines.
How Pharma Must Evolve in a Competitive Therapeutic Landscape
July 15th 2025In the second part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, suggests how pharma companies should revise their market access and pricing models to align with the evolving landscape.
A Look Under the Hood of Medicaid Support
July 11th 2025In the final part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, details the role that academic medical centers play in shaping Medicaid policy.
Peer Exchange: How Pharma Can Detect Supply Chain Failures Before They Happen (Episode 3)
July 11th 2025In the third part of this roundtable discussion, a panel of thought leaders explore the value of serialization, data sharing, and predictive analytics in identifying potential quality issues before they arise.
Sustaining Regulatory Engagement Through Industry and Advocacy Collaboration
July 10th 2025Bruce Leuchter, CEO, Neurvati, explains how industry and advocacy groups can work together to ensure patient and caregiver perspectives continue to inform regulatory decisions—even without a formal public engagement pathway.
Rising Costs, Shrinking Margins
July 9th 2025In the second part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, outlines how the federal cap on Medicaid provider taxes could affect access to care for Medicaid patients.
The Evolution of the CGT Launch and Distribution Model
July 2nd 2025In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts how he anticipates the model growing over the next three to five years, especially as global demand and regulatory complexities increase.
How Patient Advocacy Is Guiding Rare Disease Drug Development
July 1st 2025Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how patient and caregiver insights shape drug development, regulatory decisions, and payer considerations in rare diseases.